Prescription Drug Affordability Board - Group Purchasing Board For Rx We Can Afford
Impact
The implementation of H7185 is anticipated to create a regulatory framework that puts a check on the rising costs of prescription drugs in Rhode Island. It aims to alleviate financial burdens on both the state's healthcare system and residents by potentially setting upper limits on drug prices. By collecting data from drug manufacturers and insurance providers, the board will be positioned to oversee pricing models and ensure they align with affordability for consumers. This may also encourage pharmaceutical companies to be more transparent about their pricing structures and business operations.
Summary
House Bill 7185 establishes a Prescription Drug Affordability Board in Rhode Island, tasked with evaluating and regulating the prices of prescription drugs to address affordability challenges faced by state residents. The board will conduct cost reviews of drugs that have a significant financial impact on healthcare expenditures and patient out-of-pocket costs. The bill emphasizes the board's independence and authority in making decisions concerning the oversight of drug prices and its interaction with stakeholders in the healthcare system.
Contention
Notably, the establishment of the Prescription Drug Affordability Board may stir debate surrounding the balance between regulatory oversight and corporate autonomy. Proponents argue it is a necessary step towards ensuring medication access for all residents, while critics may view it as government overreach into the pharmaceutical market. The stakeholder council, comprising various representatives from related fields, including healthcare and economic sectors, will provide necessary input, yet may signal a complex dynamic of interests that could impact the board’s effectiveness in achieving its affordability goals.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.